NTRK1 and cancer: MGCD516 (Mirati Therapeutics Inc., San Diego, CA, USA) is another multi-kinase inhibitor in a phase 1/1b clinical trial (NCT02219711) for patients with advanced cancers expressing rearranged MET, RET, AXL, NTRK1, or NTRK3 genes.